Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy for Extracranial Oligometastatic Breast Cancer
NCT04646564Phase 3Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2021; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04646564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646564.